Angiodynamics announces publication of preserve study of nanoknife® system for prostate tissue ablation in european urology

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of results from the preserve study, which assessed the safety and effectiveness of irreversible electroporation (ire) with the nanoknife system to ablate prostate tissue in patients with intermediate.
ANGO Ratings Summary
ANGO Quant Ranking